New drug shows promise for fatty liver – but Long-Term control needed
Disease control
Completed
This study tested a new drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat over 48 weeks. Participants were randomly assigned to receive DD01 or a placebo, and researchers me…
Phase: PHASE2 • Sponsor: Neuraly, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC